GlassScriptPhysician profile
Priscilla E Leibel
NPI 1730652439
$11,689.14
in general payments reported to CMS, 2019-2025
28 companies · $3,522 in 2025
The $3,522 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,587 · 2023: $3,222 · 2024: $3,357 · 2025: $3,522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $60.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,040.86 |
| Education | $60.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,005.67 | 2022-2025 | |
| Janssen Biotech, INC. | $1,602.56 | 2022-2025 | Stelara, Tremfya, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,261.76 | 2022-2025 | Xifaxan, Trulance, Relistor |
| Genzyme Corporation | $805.88 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $712.07 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $499.16 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $455.36 | 2022-2025 | Ibsrela |
| Pfizer INC. | $376.85 | 2022-2025 | |
| Madrigal Pharmaceuticals | $371.11 | 2025 | Rezdiffra |
| Lilly USA, LLC | $359.44 | 2024-2025 | Omvoh |
| Evoke Pharma, INC. | $343.06 | 2022-2025 | Gimoti |
| Qol Medical, LLC | $314.25 | 2024-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $248.19 | 2022-2025 | Eohilia, Entyvio, Gattex |
| Celltrion USA INC. | $213.45 | 2024-2025 | Vegzelma |
| Redhill Biopharma INC. | $179.00 | 2022-2023 | Talicia, Aemcolo, Movantik |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $163.46 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $150.26 | 2024-2025 | Vowst, Zenpep |
| Ipsen Biopharmaceuticals, INC | $117.78 | 2024-2025 | Iqirvo, Bylvay |
| Celgene Corporation | $98.27 | 2022-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $95.49 | 2022-2023 | |
| Braintree Laboratories, INC. | $74.97 | 2022-2024 | Suflave, Sutab |
| Ironwood Pharmaceuticals, INC | $74.06 | 2023-2024 | Linzess |
| Intercept Pharmaceuticals, INC. | $56.64 | 2023-2025 | Ocaliva |
| Amag Pharmaceuticals, INC. | $30.84 | 2022 | |
| Merck Sharp & Dohme LLC | $28.30 | 2023 | Dificid |
| Novo Nordisk INC | $19.00 | 2025 | Wegovy |
| Sandoz INC. | $18.73 | 2023 | Hyrimoz |
| Azurity Pharmaceuticals, INC. | $13.53 | 2025 | Suflave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priscilla Leibel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.